Results 141 to 150 of about 45,614 (245)

Urticaria meter

open access: yesIndian Journal of Dermatology, 2012
openaire   +3 more sources

A Case for Anti‐IgE Vaccination

open access: yesAllergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff   +3 more
wiley   +1 more source

Urticaria Pigmentosa [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1937
openaire   +2 more sources

Microglial reactivity and nodule formation are associated with Synaptodendritic damage in the brains of people with HIV‐1

open access: yesBrain Pathology, EarlyView.
Despite effective ART, neurocognitive impairment persists in people with HIV. Brains from PWH present exacerbated microgliosis and formation of microglial nodules that are actively engaged in neuronal phagocytosis, resulting in neuronal injury and dendritic loss.
Roberta S. Dos Reis   +12 more
wiley   +1 more source

Physician estimation of the prevalence and clinical impact of chronic urticaria: results of the global, multicenter UCARE CU-PAPER study. [PDF]

open access: yesFront Allergy
Kern BM   +9 more
europepmc   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Spleen tyrosine kinase (SYK) has broad biological functions in inflammation and immunity. The orally administered SYK inhibitor BI 894416 was investigated in a single‐rising‐dose Phase I study in healthy volunteers and in a combined single‐ and multiple‐rising‐dose Phase Ib study in patients with mild asthma ...
Saskia Carstensen‐Aurèche   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy